#Glp1

A new class of weight‑loss compounds targets a different brain pathway and has shown promising results in animal studies. The engineered molecule reduces appetite and improves insulin response without the nausea that often accompanies current drugs. Researchers identified a peptide called octadecaneuropeptide (ODN) produced by support cells in the hindbrain, then designed a drug-like derivative, tridecaneuropeptide (TDN). In obese mice and emesis-capable musk shrews, TDN reduced food intake and improved glucose handling without triggering sickness. The work highlights a potential path to obesity and diabetes therapies that may be easier for patients to tolerate and for health systems to deliver.

Thai consumers face mounting risks from sophisticated international scam networks operating fake online stores that exploit growing demand for weight-loss medications, particularly products claiming to mimic popular diabetes treatments like Ozempic and Mounjaro. Investigative research reveals that more than 140 websites have pivoted from fashion retail facades to targeting vulnerable weight-loss seekers with fraudulent “plant-based oral solutions” that promise pharmaceutical-grade results without medical supervision. These ghost store operations employ stolen professional identities, artificial intelligence-generated testimonials, and elaborate fake endorsements to exploit Thailand’s thriving digital marketplace and cultural emphasis on physical appearance.

Thai consumers are being urged to exercise heightened caution when purchasing weight-loss solutions online, following revelations from Australia about a new wave of “ghost stores” scamming buyers with fake GLP-1 products and predatory advertising—a scam that could easily spread to Thailand’s thriving digital marketplaces. These ghost stores, uncovered by investigative journalists at The Guardian, have been found impersonating real businesses and health experts to sell supposedly plant-based oral supplements that mimic the effects of popular diabetes and weight-loss medications such as Ozempic and Mounjaro, posing direct risks to consumer financial safety and, more alarmingly, their health (theguardian.com).

A surge in ghost online stores is targeting Thai weight-loss seekers with counterfeit GLP-1 products that imitate popular medications like Ozempic and Mounjaro. Investigations show more than 140 websites shifting from fashion fronts to fraudulent claims of “plant-based oral solutions” that promise pharmaceutical-grade results without medical supervision. These operations rely on stolen professional images, AI-generated testimonials, and fake endorsements to build trust among Thailand’s digital shoppers.

Global shortages and rising prices for genuine GLP-1 medicines have created fertile ground for scammers. Real treatments such as semaglutide and tirzepatide offer meaningful weight-management benefits for people with obesity or metabolic disorders, driving demand that illicit operators exploit through sophisticated deception. The result is a perilous mix of medical misinformation and aggressive online marketing.

Scientists have uncovered a potential natural alternative to Ozempic, the popular diabetes and weight-loss medication, by tapping into the power of gut microbes that can regulate blood sugar levels and curb sugar cravings. The latest research, led by a team from Jiangnan University in China and published in Nature Microbiology, points to the gut bacterium Bacteroides vulgatus and its metabolites as key players in stimulating the body’s natural production of glucagon-like peptide-1 (GLP-1), a hormone crucial for maintaining healthy blood sugar and satiety. While initial results are based on animal studies, this discovery raises fresh hope for safer, more accessible strategies to treat diabetes—potentially transforming the landscape for millions of people in Thailand and around the globe who struggle with blood sugar management and sugar cravings [ScienceAlert].

A new line of research suggests that gut bacteria may offer a natural approach to managing blood sugar and reducing sugar cravings. In a study led by researchers at Jiangnan University in China and published in Nature Microbiology, the gut bacterium Bacteroides vulgatus and its byproducts appear to stimulate the body’s own GLP-1 production, a hormone that promotes fullness and helps regulate glucose. While findings are preliminary and based on animal studies, they point toward future dietary or probiotic strategies that could complement or reduce reliance on medications like Ozempic. The research also raises hopes for Thailand and other countries facing rising diabetes rates, where accessible, lifestyle-based options are highly valued by patients and clinicians.

A fitness influencer with more than five million followers has sparked a widespread ethics discussion in Thailand after revealing in a YouTube video that her recent weight loss benefited from a GLP-1 medication, not just diet and exercise. The video titled “Let’s talk: Therapy, GLP-1 & The Truth About My Recent Weight Loss” has prompted conversations about transparency and the responsibilities of online wellness creators.

The influencer previously promoted a popular $200 weight-loss course focused on macro tracking and lifestyle changes. She disclosed that, in addition to her usual methods, she used a GLP-1 medicine under medical supervision. She stressed that GLP-1s are not magic and that she continues to follow diet and exercise plans. Reactions among followers were mixed; some accused her of withholding information that could affect purchasing decisions and refunds.

A social media fitness influencer with over five million followers has ignited a widespread controversy after publicly sharing that her recent weight loss success involved the use of a GLP-1 class medication, commonly known by names such as Ozempic and Mounjaro. The disclosure, made in a YouTube video titled “Let’s talk: Therapy, GLP-1 & The Truth About My Recent Weight Loss,” has set off heated discussions about transparency, ethical responsibility, and the realities of the online wellness industry.

A worldwide surge in GLP-1 medicines, including Ozempic (semaglutide), has drawn attention for strong weight-management effects. In Thailand, where cultural norms shape body image and eating habits, experts warn about potential risks for people with eating disorders.

Ozempic works by mimicking a natural hormone that helps regulate insulin and slows stomach emptying, making people feel full sooner. While it supports weight loss and better blood sugar control, its appetite-suppressing action could affect individuals prone to eating disorders such as anorexia or bulimia. Health professionals caution that such medications might worsen unhealthy eating patterns in vulnerable patients. Medical teams emphasize thorough evaluation before prescribing these drugs, particularly for people with malnutrition or complex nutritional histories.